The prize is awarded to a company that has distinguished itself by contributing to societal benefit emphasizing the importance of a successful life science industry in Sweden.
“It is a great honor for BioArctic to receive this award. It is gratifying and inspiring for us all at BioArctic. We are proud of our successes. The award is a confirmation of BioArctic’s contributions to the continued positive development of the Swedish life science industry,” says Gunilla Osswald, CEO of BioArctic.
SwedenBIO rewards BioArctic for the company’s strong collaborations with academia as well as global pharma companies, and a high scientific ambition, which has given BioArctic a portfolio of innovative projects for the treatment of diseases of the central nervous system, an area with growing medical and societal needs. SwedenBIO further emphasizes that BioArctic has attracted international attention and since the start in 2003 been built up and expertly financed by dedicated founders and strong and equal management to a listing on Nasdaq Stockholm Mid Cap in 2017. The listing is one of the biggest share issues that have been made in Swedish biotech since the year 2000.
SwedenBIO’s CEO Jonas Ekstrand says that BioArctic is an excellent example of the great synergies that can be achieved by utilizing collaborations between research in various sectors to find solutions to medical challenges. “Hopefully the company’s research will give patients access to disease modifying treatments for Alzheimer’s and Parkinson’s diseases, creating value also for their families and for society,” says Jonas Ekstrand.
SwedenBIO is the national trade association for life science in Sweden and the SwedenBIO Award is the industry’s own prize. This year’s prize is the twelfth in order and was presented together with the prize sponsor HealthCap.
This year’s jury consisted of the board of SwedenBIO: Lars Adlersson, Six Year Plan, Eva Sjökvist Saers, APL, Sarah Fredriksson, P.U.L.S., Kirsti Gjellan, Sobi, Magnus Björsne, AstraZeneca, Per Samuelsson, HealthCap, Lotta Ljungqvist, GE, Carl-Johan Spak, Recipharm and Johan Brun, Pfizer.
Photo of Jonas Ekstrand, CEO SwedenBIO, Gunilla Osswald, CEO BioArctic and Björn Odlander, Managing Partner HealthCap. Photographer: Mengjing Ke/SwedenBIO